SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: david thor who wrote (626)9/1/1997 4:58:00 PM
From: D.Right   of 2173
 
Dear Dave:

Unfortunately, the half life of insulin inside human body is very short, no drug can reduce the frequency of insulin injection if a patient can't make enough of it. However, pramlintide has shown in the two clinical trials that it can reduce the amount of insulin used by both type I and II patients. I believe the WLA's drug can also reduce the amount of insulin used by type II patient and LGND's drug has the same effect in animal test. As for diet and exercise, no good medicine can replace that. All the promises of these new medicines are to make patients healthier not less work.

Have a good Labor Day

D.Right
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News